Loading
Every dated change on the records linked to NTRK fusion-positive non-small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Repotrectinib produced responses in 79 percent of ROS1 inhibitor-naive patients (median progression-free survival 35.
A milestone in how this cancer is treated.